Bayer and RNA firm sign cancer pact

Bayer is teaming up with the start-up NextRNA Therapeutics to develop two small-molecule drugs for unspecified cancers. Both programs will target long noncoding RNAs, a type of RNA that doesn’t code for proteins but instead interacts with them and modulates their activity. Bayer will pay NextRNA up to $547 million in up-front and milestone payments.

Authors

Publication Details

Journal
C&EN Global Enterprise
Published
2024-09-02
DOI
https://doi.org/10.1021/cen-10227-buscon16
Primary Topic
Biomedical Ethics and Regulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Bayer and RNA firm sign cancer pact

Rowan Walrath
C&EN Global Enterprise
Biomedical Ethics and Regulation
article

Bayer and RNA firm sign cancer pact

Rowan Walrath
article en

Abstract

Bayer is teaming up with the start-up NextRNA Therapeutics to develop two small-molecule drugs for unspecified cancers. Both programs will target long noncoding RNAs, a type of RNA that doesn’t code for proteins but instead interacts with them and modulates their activity. Bayer will pay NextRNA up to $547 million in up-front and milestone payments.

C&EN Global EnterpriseVol. 102(27)
Openalex Percentile: Top 80%
Biomedical Ethics and Regulation
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Bayer and RNA firm sign cancer pact — Rowan Walrath · C&EN Global Enterprise (2024) | TGRS Research Map | TGRS